Johnson & Johnson (JNJ) has delivered a strong first quarter performance, exceeding market expectations for both earnings and revenue. The company’s robust sales totaled $21.89 billion in the first quarter of 2025, reflecting a 2.4% increase compared to the same period last year. Driven by continued success in its innovative medicine and medical technology segments, JNJ’s profits soared, with net earnings jumping to $10.99 billion from just $3.25 billion during the previous year. This significant boost was fueled by robust sales of oncology drugs like Darzalex and Erleada within the Innovative Medicine division, as well as strong performance in cardiovascular and vision care products within MedTech. 🌎 Sales growth was particularly notable in the U.S., increasing by 5.9% while international sales experienced a slight decline of 1.8%. Despite currency fluctuations impacting international markets, the company’s operational growth remained positive across most regions.